Bumpy EU Review Ends Well For Selinexor Filing

 
• By Neena Brizmohun

Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.

Diagnosis of Multiple Myeloma. Test tubes or bottles for blood, stethoscope and laboratory hematology analysis surrounded by text title of diagnosis of Multiple Myeloma lie in the doctor workplace
Karyopharm's multiple myeloma treatment could win EU approval soon • Source: Shutterstock

Karyopharm Therapeutics has taken a major step forward towards securing pan-EU marketing authorization for its multiple myeloma treatment, Nexpovio (selinexor).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography